FrançaisAre analysts right about STAAR Surgical Company (STAA)?
📈 See the interactive version (live chart) →
Historical analyst accuracy
For STAAR Surgical Company, we replayed every analyst price target of the past 12 months and measured the real outcome: 26% were profitable, average return +10% (58 calls). At 3 months: +4% average return (40% profitable). The higher the %, the more often analysts were right on this stock.
Most reliable analysts on this stock (past track record)
Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| Canaccord Genuity | 16 | 38% | +33% |
| Needham | 9 | 0% | -31% |
| Stephens & Co. | 7 | 29% | +18% |
| Mizuho | 6 | 0% | -43% |
| BTIG | 5 | 20% | -16% |
Frequently asked questions
Is STAAR Surgical Company a buy right now?
The analyst consensus on STAAR Surgical Company (STAA) is "Hold" (9 bullish, 2 bearish calls over 12 months). This is not advice: historically, 26% of their targets on this stock turned out profitable over 1 year.
What is STAAR Surgical Company's price target?
The median 12-month price target is $28.00 (+25% vs $22.39), ranging from $19.00 to $37.00 (7 analysts).
Are analysts accurate on STAAR Surgical Company?
Over 1 year, 26% of analyst targets on STAAR Surgical Company were profitable, for an average return of +10% (across 58 timestamped calls). This is JPI Invest's accuracy metric.
What is the STAAR Surgical Company stock forecast?
Analysts target a median of $28.00 within 12 months, i.e. +25% vs the current price. The most bullish targets $37.00, the most cautious $19.00.
What is the STAAR Surgical Company stock forecast for 2026 or long term (2030)?
Note: analyst targets are 12-month (median $28.00, +25%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (26%), and the stock's past trajectory.
Is STAAR Surgical Company overvalued?
Detailed valuation data for STAAR Surgical Company is available in the interactive analysis.
📊 See the full interactive analysis of STAAR Surgical Company →
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.